十二烷基二甲基(alpha-甲基苯甲酰甲基)溴化铵 | 31351-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 十二烷基二甲基(alpha-甲基苯甲酰甲基)溴化铵
• 英文名称: N-dodecyl-N-methylephedrinium bromide
• 英文别名: (+/-)-1,1-Phenylhydroxypropyl-2-dodecyldimethylammonium；Dodecyl(2-hydroxy-1-methyl-2-phenylethyl)dimethylammonium bromide；dodecyl-(1-hydroxy-1-phenylpropan-2-yl)-dimethylazanium;bromide
• CAS: 31351-20-9
• 化学式: Br*C₂₃H₄₂NO
• 分子量: 428.497
• InChiKey: GOIUTZPQFMGLAH-UHFFFAOYSA-M

物化性质

• 熔点：
  80-82 °C(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  S-p-tolyl-S-vinyl-N-phthalimidosulfoximine 、 硝基乙烷 、 十二烷基二甲基(alpha-甲基苯甲酰甲基)溴化铵 生成 2-[[(4-methylphenyl)-(3-nitrobutyl)-oxo-λ6-sulfanylidene]amino]isoindole-1,3-dione
  参考文献：
  名称：

  ANNUNZIATA R.; CINGUINI M.; COLONNA S., J. CHEM. SOC. PERKIN TRANS., PART 1, 1980, NO 11, 2422-2424

  摘要：

  DOI：
• 作为产物：
  描述：

  L-N-甲基麻黄碱盐酸盐 、 溴代十二烷 以98%的产率得到
  参考文献：
  名称：

  CHEN, HONGQING;LI, SHULIAN;HAN, SHITIAN;XIE, HONG, CHEMISTRY, 1984, N 6, 13-14

  摘要：

  DOI：

文献信息

• 5-LIPOXYGENASE INHIBITORS
  申请人：Verma Kumar Ashwani

  公开号：US20080021080A1

  公开（公告）日：2008-01-24

  The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

  本发明涉及5-脂氧酶抑制剂。本文所披露的化合物可用于治疗支气管哮喘、慢性阻塞性肺疾病、关节炎、1型糖尿病、多发性硬化症、移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、荨麻疹、特应性皮炎、过敏性鼻炎和其他炎症性和自身免疫性疾病的治疗。本文还提供了所披露化合物的制备方法、含有所披露化合物的制药组合物以及它们作为5-脂氧酶抑制剂的用途。
• Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1834953A1

  公开（公告）日：2007-09-19

  The present invention relates to 5-lipoxygenase inhibitors of formula I. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type 1 diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

  本发明涉及式I的5-脂氧合酶抑制剂。本文所披露的化合物可用于治疗支气管哮喘、慢性阻塞性肺疾病、关节炎、1型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、荨麻疹、特应性皮炎、过敏性鼻炎以及其他炎症和自身免疫性疾病的治疗。本文还提供了所披露的化合物的制备方法、含有所披露的化合物的制药组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
  申请人：Pfizer Products Inc.

  公开号：EP1081144A2

  公开（公告）日：2001-03-07

  A process is described for preparing a compound of Formula (1.3.0): comprising: establishing a reaction mixture consisting of in an aprotic solvent; in the presence of NaOH or KOH; optionally in the presence of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt; followed by heating said reaction mixture under a nitrogen atmosphere; in a preferred embodiment the aprotic solvent is DMSO, the strong base in solid form is NaOH in powder or pellet form, and the phase transfer catalyst is tetra-n-butylammonium chloride (TBAC); wherein the starting material of Formula (2.0.0) is prepared as follows: are reacted together in a solvent consisting of a straight or branched chain aliphatic alcohol; in the presence of a strong base consisting of NaOH or KOH; further in the presence of a transition metal catalyst comprising a palladium metal complex; and still further in the presence of an auxiliary ligand comprising a bidentate, chiral, axially dissymmetric aromatic compound of Formula (5.5.0) or (5.5.1):

  本发明描述了一种制备式（1.3.0）化合物的工艺： 包括 在非沸腾溶剂中；在 NaOH 或 KOH 存在下；可选择在相转移催化剂，特别是季铵盐或鏻盐存在下； 然后在氮气环境下加热所述反应混合物； 在一个优选的实施方案中，壬烷溶剂为二甲基亚砜，固体形式的强碱为粉末状或颗粒状的 NaOH，相转移催化剂为四正丁基氯化铵（TBAC）； 其中式（2.0.0）的起始原料按如下方法制备： 在由直链或支链脂肪醇组成的溶剂中一起反应 在由直链或支链脂肪醇组成的溶剂中；在由 NaOH 或 KOH 组成的强碱存在下；进一步在由钯金属络合物组成的过渡金属催化剂存在下；以及进一步在由式 (5.5.0) 或 (5.5.1) 的双齿、手性、轴向不对称芳香化合物组成的辅助配体存在下：
• POLYOLEFIN GRAFT COPOLYMER
  申请人：KANEKA CORPORATION

  公开号：EP1671985A1

  公开（公告）日：2006-06-21

  The present invention provides a polyolefin copolymer in which an olefin monomer is graft-copolymerized to modified particles of a metallic compound. The polyolefin graft copolymer can be obtained by graft-copolymerizing the olefin monomer to modified particles of a metallic compound in the presence of a coordination polymerization catalyst in the presence of, particularly, a coordination polymerization catalyst of a late transition metal complex. Further, the property of a polyolefin resin can be improved by blending the polyolefin graft copolymer to a polyolefin resin.

  本发明提供了一种聚烯烃共聚物，其中烯烃单体与金属化合物的改性颗粒进行接枝共聚。该聚烯烃接枝共聚物可通过在配位聚合催化剂（尤其是后期过渡金属络合物的配位聚合催化剂）存在下，将烯烃单体接枝共聚到金属化合物的改性颗粒上而获得。此外，通过将聚烯烃接枝共聚物与聚烯烃树脂混合，可以改善聚烯烃树脂的性能。
• Epoxy resin compositions, methods of making same, and articles thereof
  申请人：Dow Global Technologies LLC

  公开号：EP2746312A2

  公开（公告）日：2014-06-25

  Epoxy resins comprising a diglycidyl ether of Formula 1 as defined herein are described. The diglycidyl ether contains a cycloaliphatic ring of 3-5 carbon atoms. The epoxy resins are made by a method comprising the steps of: (a) forming a reaction mixture comprising a diol of Formula 3 as defined herein, an epihalohydrin, a phase transfer catalyst, and optionally an organic solvent; (b) contacting a basic acting substance and water with the reaction mixture of step (a); (c) washing the mixture of step (b) with an aqueous solvent to substantially remove salts; and (d) isolating the epoxy resin. Curable and cured compositions comprising the epoxy resins are also disclosed. The epoxy resins have increased glass transition temperatures and reduced viscosity compared to epoxy resins derived from cyclohexanedimethanol.

  所述环氧树脂包含如本文所定义的式 1 的二缩水甘油醚。二缩水甘油醚含有 3-5 个碳原子的环脂族环。环氧树脂的制造方法包括以下步骤(a) 形成反应混合物，该混合物包含本文定义的式 3 的二元醇、表卤代烃、相转移催化剂和可选的有机溶剂；(b) 将碱性作用物质和水与步骤(a)的反应混合物接触；(c) 用水性溶剂洗涤步骤(b)的混合物，以基本上除去盐；以及 (d) 分离环氧树脂。还公开了包含环氧树脂的可固化和固化组合物。与从环己烷二甲醇中提取的环氧树脂相比，环氧树脂的玻璃化温度更高，粘度更低。